Edwards Lifesciences Corp
EW
查看详细走势图
81.490USD
-0.370-0.45%
收盘 01/29, 16:00（美东）报价延迟15分钟
47.32B总市值
34.70市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.45%
5天
-3.49%
1月
-6.27%
6月
+1.27%
今年开始到现在
-4.41%
1年
+14.56%
查看详细走势图
TradingKey Edwards Lifesciences Corp股票评分
单位: USD 更新时间: 2026-01-28操作建议
Edwards Lifesciences Corp当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在医疗设备与耗材行业排名11/205位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价96.46。中期看，股价处于平稳状态。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Edwards Lifesciences Corp评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
29°C
过冷
过热
中性
Edwards Lifesciences Corp亮点
亮点风险
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
利润高增长
公司净利润处于行业前列，最新年度总收入5.44B美元
估值合理
公司最新PE估值34.86，处于3年历史合理位
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓，最新持仓市值7.71K
分析师目标
根据
34
位分析师
买入
评级
96.459
目标均价
+15.30%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Edwards Lifesciences Corp新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Edwards Lifesciences Corp简介
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
公司代码EW
公司Edwards Lifesciences Corp
CEOZovighian (Bernard J)
网址https://www.edwards.com
相关品种
